{"url_path":"/sec/inbs/8-k/2026-06-02/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-02","source_url":"https://www.sec.gov/Archives/edgar/data/1725430/0001493152-26-026780-index.html","accession_number":"0001493152-26-026780","cik":"0001725430","ticker":"INBS","issuer_name":"INTELLIGENT BIO SOLUTIONS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1725430/0001493152-26-026780-index.html","primary_entity_key":"0001725430","primary_entity_name":"INTELLIGENT BIO SOLUTIONS INC."},"word_count":160,"has_tables":true,"body_markdown":"**Item\n7.01 Regulation FD Disclosure.**\n\n \n\nOn\nJune 2, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing\nthe initiation of a multi-site Method Comparison Study to support its FDA 510(k) submission for U.S. market clearance of its Intelligent\nFingerprinting Drug Screening System for the opiate codeine. A copy of the press release is furnished as Exhibit 99.1 to this Current\nReport on Form 8-K. The foregoing disclosure is qualified in its entirety by the full text of the Press Release.\n\n \n\nThe\ninformation contained in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed\nto be “filed” for the purpose of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall\nit be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, unless specifically\nidentified therein as being incorporated by reference."}